Receptor tyrosine kinase gene copy numbers and protein expression in astrocytic brain tumors : With special reference to KIT, PDGFRA, VEGFR2 and EGFR
Year: 2012
Type: dissertation
Study design: Observational Study
Abstract: In the present study we investigated expression and amplification of KIT, PDGFRA, VEGFR2 and EGFR in glioblastomas and in lower grade gliomas, and analyzed the hot spot mutation sites of KIT, PDGFRA and EGFR genes for presence of mutations in glioblastoma. Furthermore, we evaluated expression of KIT, SCF and VEGFR2 in paediatric brain tumors and in tumour endothelial cells, and studied the intratumoral heterogeneity of EGFR and KIT amplifications in primary glioblastomas and astrocytomas. Mutations turned out to be infrequent in these genes suggesting that neither primary nor secondary glioblastomas are usually driven by KIT or PDGFRA mutations, or by EGFR kinase domain mutations. Amplifications of KIT, VEGFR2, PDGFRA and EGFR turned out to be frequent in glioblastoma. KIT was amplified in 47% and VEGFR2 in 39% out of the 43 primary glioblastomas investigated, and PDGFRA in 29%. Presence of KIT, PDGFRA and VEGFR2 amplifications were strongly associated (p < 0.0001 for each pair wise comparison) suggesting co-amplification. We investigated presence of gene amplifications also in other types of gliomas either in tumour samples collected at the time of the diagnosis or in samples collected at the time of tumour recurrence. In tumour tissue samples collected at the time of the diagnosis KIT and PDGFRA amplifications turned out to be more frequent in anaplastic astrocytomas than in astrocytomas, oligodendrogliomas and oligoastrocytomas. Amplified KIT was more frequently present in recurrent gliomas than in newly diagnosed. Pilocytic astrocytomas studied did not harbour amplification of KIT. KIT expression was common in tumour endothelial cells in pilocytic astrocytomas, and endothelial cell KIT was frequently activated. Tumour endothelial cell KIT expression was associated with a young age at the time of the diagnosis. Ependymomas also frequently expressed KIT in endothelial cells, and its expression tended to be associated with a young age at the time of the diagnosis. Finally, we investigated heterogeneity of KIT and EGFR amplification and their protein products in gliomas by studying several tissue blocks from each tumour. EGFR amplification was found in ten out of the 15 glioblastomas studied when analysis was carried out from only one tissue block, and in 11 cases when all available tissue blocks were analyzed. KIT was amplified in six out of the 15 index glioblastoma tissue blocks, but in 10 glioblastomas when all tissue blocks were analyzed. These findings suggest that glioblastomas show marked heterogeneity in KIT amplifications and that heterogeneity is less for EGFR amplifications.
Author: Marjut Puputti
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2170138671
